The incidence of new vertebral compression fractures in women after kyphoplasty and factors involved

Eun Su Moon, Hak Sun Kim, Jin Oh Park, Seong Hwan Mon, Hwan Mo Lee, Dong Eun Shin, Jung Won Ha, Eun Kyoung Ahn, Dong Jun Shim, Jun Young Chung

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Purpose: To identify the incidence of new vertebral compression fractures in women after kyphoplasty and to analyze influential factors in these patients. Materials and Methods: One hundred and eleven consecutive female patients with osteoporotic vertebral compression fractures (VCFs) underwent kyphoplasty at 137 levels. These patients were followed for 15.2 months postoperatively. For the survey of new vertebral compression fractures, medical records and x-rays were reviewed, and telephone interviews were conducted with all patients. Results: During that time 20 (18%) patients developed new VCFs. The rate of occurrence of new VCFs in one year was 15.5% using a Kaplan-Meier curve. Body mass index (BMI), symptom duration and kyphoplasty level were the statistically significant factors between the patient groups both with and without new VCFs after kyphoplasty. In the comparison between the adjacent and remote new VCF groups, the adjacent new VCF group showed a larger amount of polymethyl methacrylate (PMMA) use during kyphoplasty (p <0.05). Before kyphoplasty, 9.9% of the patients had been prescribed medication for osteoporosis, and 93.7% of the patients started or continued medication after kyphoplasty. The development of new VCFs was affected by the number of vertebrae involved in the kyphoplasty. However, the lower incidence rate (15.5%) of new compression fractures might be due to a greater percentage (93.7% in our study) of patients taking anti-osteoporotic medication before and/or after kyphoplasty. Conclusion: When kyphoplasty is planned for the management of patients with osteoperotic VCFs, the application of a small amount of PMMA can be considered in order to lower the risk of new fractures in adjacent vertebrae. The post-operative use of anti-osteoporotic medication is recommended for the prevention of new VCFs.

Original languageEnglish
Pages (from-to)645-652
Number of pages8
JournalYonsei medical journal
Volume48
Issue number4
DOIs
Publication statusPublished - 2007 Aug 1

Fingerprint

Kyphoplasty
Compression Fractures
Incidence
Polymethyl Methacrylate
Spine
Osteoporosis
Statistical Factor Analysis
Medical Records

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Moon, Eun Su ; Kim, Hak Sun ; Park, Jin Oh ; Mon, Seong Hwan ; Lee, Hwan Mo ; Shin, Dong Eun ; Ha, Jung Won ; Ahn, Eun Kyoung ; Shim, Dong Jun ; Chung, Jun Young. / The incidence of new vertebral compression fractures in women after kyphoplasty and factors involved. In: Yonsei medical journal. 2007 ; Vol. 48, No. 4. pp. 645-652.
@article{fb570762f68d4d6e867e9bc629d8a8d8,
title = "The incidence of new vertebral compression fractures in women after kyphoplasty and factors involved",
abstract = "Purpose: To identify the incidence of new vertebral compression fractures in women after kyphoplasty and to analyze influential factors in these patients. Materials and Methods: One hundred and eleven consecutive female patients with osteoporotic vertebral compression fractures (VCFs) underwent kyphoplasty at 137 levels. These patients were followed for 15.2 months postoperatively. For the survey of new vertebral compression fractures, medical records and x-rays were reviewed, and telephone interviews were conducted with all patients. Results: During that time 20 (18{\%}) patients developed new VCFs. The rate of occurrence of new VCFs in one year was 15.5{\%} using a Kaplan-Meier curve. Body mass index (BMI), symptom duration and kyphoplasty level were the statistically significant factors between the patient groups both with and without new VCFs after kyphoplasty. In the comparison between the adjacent and remote new VCF groups, the adjacent new VCF group showed a larger amount of polymethyl methacrylate (PMMA) use during kyphoplasty (p <0.05). Before kyphoplasty, 9.9{\%} of the patients had been prescribed medication for osteoporosis, and 93.7{\%} of the patients started or continued medication after kyphoplasty. The development of new VCFs was affected by the number of vertebrae involved in the kyphoplasty. However, the lower incidence rate (15.5{\%}) of new compression fractures might be due to a greater percentage (93.7{\%} in our study) of patients taking anti-osteoporotic medication before and/or after kyphoplasty. Conclusion: When kyphoplasty is planned for the management of patients with osteoperotic VCFs, the application of a small amount of PMMA can be considered in order to lower the risk of new fractures in adjacent vertebrae. The post-operative use of anti-osteoporotic medication is recommended for the prevention of new VCFs.",
author = "Moon, {Eun Su} and Kim, {Hak Sun} and Park, {Jin Oh} and Mon, {Seong Hwan} and Lee, {Hwan Mo} and Shin, {Dong Eun} and Ha, {Jung Won} and Ahn, {Eun Kyoung} and Shim, {Dong Jun} and Chung, {Jun Young}",
year = "2007",
month = "8",
day = "1",
doi = "10.3349/ymj.2007.48.4.645",
language = "English",
volume = "48",
pages = "645--652",
journal = "Yonsei Medical Journal",
issn = "0513-5796",
publisher = "Yonsei University College of Medicine",
number = "4",

}

Moon, ES, Kim, HS, Park, JO, Mon, SH, Lee, HM, Shin, DE, Ha, JW, Ahn, EK, Shim, DJ & Chung, JY 2007, 'The incidence of new vertebral compression fractures in women after kyphoplasty and factors involved', Yonsei medical journal, vol. 48, no. 4, pp. 645-652. https://doi.org/10.3349/ymj.2007.48.4.645

The incidence of new vertebral compression fractures in women after kyphoplasty and factors involved. / Moon, Eun Su; Kim, Hak Sun; Park, Jin Oh; Mon, Seong Hwan; Lee, Hwan Mo; Shin, Dong Eun; Ha, Jung Won; Ahn, Eun Kyoung; Shim, Dong Jun; Chung, Jun Young.

In: Yonsei medical journal, Vol. 48, No. 4, 01.08.2007, p. 645-652.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The incidence of new vertebral compression fractures in women after kyphoplasty and factors involved

AU - Moon, Eun Su

AU - Kim, Hak Sun

AU - Park, Jin Oh

AU - Mon, Seong Hwan

AU - Lee, Hwan Mo

AU - Shin, Dong Eun

AU - Ha, Jung Won

AU - Ahn, Eun Kyoung

AU - Shim, Dong Jun

AU - Chung, Jun Young

PY - 2007/8/1

Y1 - 2007/8/1

N2 - Purpose: To identify the incidence of new vertebral compression fractures in women after kyphoplasty and to analyze influential factors in these patients. Materials and Methods: One hundred and eleven consecutive female patients with osteoporotic vertebral compression fractures (VCFs) underwent kyphoplasty at 137 levels. These patients were followed for 15.2 months postoperatively. For the survey of new vertebral compression fractures, medical records and x-rays were reviewed, and telephone interviews were conducted with all patients. Results: During that time 20 (18%) patients developed new VCFs. The rate of occurrence of new VCFs in one year was 15.5% using a Kaplan-Meier curve. Body mass index (BMI), symptom duration and kyphoplasty level were the statistically significant factors between the patient groups both with and without new VCFs after kyphoplasty. In the comparison between the adjacent and remote new VCF groups, the adjacent new VCF group showed a larger amount of polymethyl methacrylate (PMMA) use during kyphoplasty (p <0.05). Before kyphoplasty, 9.9% of the patients had been prescribed medication for osteoporosis, and 93.7% of the patients started or continued medication after kyphoplasty. The development of new VCFs was affected by the number of vertebrae involved in the kyphoplasty. However, the lower incidence rate (15.5%) of new compression fractures might be due to a greater percentage (93.7% in our study) of patients taking anti-osteoporotic medication before and/or after kyphoplasty. Conclusion: When kyphoplasty is planned for the management of patients with osteoperotic VCFs, the application of a small amount of PMMA can be considered in order to lower the risk of new fractures in adjacent vertebrae. The post-operative use of anti-osteoporotic medication is recommended for the prevention of new VCFs.

AB - Purpose: To identify the incidence of new vertebral compression fractures in women after kyphoplasty and to analyze influential factors in these patients. Materials and Methods: One hundred and eleven consecutive female patients with osteoporotic vertebral compression fractures (VCFs) underwent kyphoplasty at 137 levels. These patients were followed for 15.2 months postoperatively. For the survey of new vertebral compression fractures, medical records and x-rays were reviewed, and telephone interviews were conducted with all patients. Results: During that time 20 (18%) patients developed new VCFs. The rate of occurrence of new VCFs in one year was 15.5% using a Kaplan-Meier curve. Body mass index (BMI), symptom duration and kyphoplasty level were the statistically significant factors between the patient groups both with and without new VCFs after kyphoplasty. In the comparison between the adjacent and remote new VCF groups, the adjacent new VCF group showed a larger amount of polymethyl methacrylate (PMMA) use during kyphoplasty (p <0.05). Before kyphoplasty, 9.9% of the patients had been prescribed medication for osteoporosis, and 93.7% of the patients started or continued medication after kyphoplasty. The development of new VCFs was affected by the number of vertebrae involved in the kyphoplasty. However, the lower incidence rate (15.5%) of new compression fractures might be due to a greater percentage (93.7% in our study) of patients taking anti-osteoporotic medication before and/or after kyphoplasty. Conclusion: When kyphoplasty is planned for the management of patients with osteoperotic VCFs, the application of a small amount of PMMA can be considered in order to lower the risk of new fractures in adjacent vertebrae. The post-operative use of anti-osteoporotic medication is recommended for the prevention of new VCFs.

UR - http://www.scopus.com/inward/record.url?scp=34848882833&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34848882833&partnerID=8YFLogxK

U2 - 10.3349/ymj.2007.48.4.645

DO - 10.3349/ymj.2007.48.4.645

M3 - Article

C2 - 17722237

AN - SCOPUS:34848882833

VL - 48

SP - 645

EP - 652

JO - Yonsei Medical Journal

JF - Yonsei Medical Journal

SN - 0513-5796

IS - 4

ER -